These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8529503)

  • 21. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Tsumura K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gliquidone ameliorates hepatic insulin resistance in streptozotocin-induced diabetic Sur1
    Zhang R; Zhou X; Sheng Q; Zhang Q; Xie T; Xu C; Zou Z; Dong J; Liao L
    Eur J Pharmacol; 2021 Sep; 906():174221. PubMed ID: 34081903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
    Suter SL; Nolan JJ; Wallace P; Gumbiner B; Olefsky JM
    Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM.
    Vaag A; Alford F; Henriksen FL; Christopher M; Beck-Nielsen H
    Diabetologia; 1995 Mar; 38(3):326-36. PubMed ID: 7758880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus.
    Tomita T; Yamasaki Y; Kubota M; Tohdo R; Katsura M; Ikeda M; Nakahara I; Shiba Y; Matsuhisa M; Hori M
    Endocr J; 1998 Apr; 45(2):165-73. PubMed ID: 9700469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin resistance seen in non-insulin dependent diabetes mellitus and hypertension.
    Kawamori R
    Hypertens Res; 1996 Jun; 19 Suppl 1():S61-4. PubMed ID: 9240767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents.
    Gulli G; Ferrannini E; Stern M; Haffner S; DeFronzo RA
    Diabetes; 1992 Dec; 41(12):1575-86. PubMed ID: 1446799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of glyburide on in vivo insulin-mediated glucose disposal.
    Simonson DC
    Am J Med; 1990 Aug; 89(2A):44S-50S; discussion 51S-53S. PubMed ID: 2117389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro.
    Müller G; Wied S
    Diabetes; 1993 Dec; 42(12):1852-67. PubMed ID: 8243832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus.
    Ludvik B; Nolan JJ; Roberts A; Baloga J; Joyce M; Bell JM; Olefsky JM
    J Clin Invest; 1997 Nov; 100(9):2354-61. PubMed ID: 9410915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (-)-BM 13.0913: a new oral antidiabetic agent that improves insulin sensitivity in animal models of type II (non-insulin-dependent) diabetes mellitus.
    Freund P; Wolff HP; Kühnle HF
    Metabolism; 1995 May; 44(5):570-6. PubMed ID: 7752903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combined therapy with insulin and oral hypoglycemic agents in diabetes mellitus].
    Takamatsu J
    Nihon Rinsho; 1990 Dec; 48 Suppl():1031-7. PubMed ID: 2086864
    [No Abstract]   [Full Text] [Related]  

  • 36. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Maifreni L; Duner E; Lisato G; Iavicoli M; Tiengo A
    Diabetologia; 1990 Nov; 33(11):688-95. PubMed ID: 2127573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.
    Goldfine AB; Patti ME; Zuberi L; Goldstein BJ; LeBlanc R; Landaker EJ; Jiang ZY; Willsky GR; Kahn CR
    Metabolism; 2000 Mar; 49(3):400-10. PubMed ID: 10726921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.
    Kolterman OG; Olefsky JM
    Diabetes Care; 1984; 7 Suppl 1():81-8. PubMed ID: 6376033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
    Lebovitz HE
    Drugs; 1992; 44 Suppl 3():21-8. PubMed ID: 1280574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NIDDM in the elderly.
    Meneilly GS; Elliott T; Tessier D; Hards L; Tildesley H
    Diabetes Care; 1996 Dec; 19(12):1320-5. PubMed ID: 8941457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.